BioLife Solutions (NASDAQ:BLFS) Raised to Buy at Wall Street Zen

BioLife Solutions (NASDAQ:BLFS) was upgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research note issued on Saturday.

Other equities research analysts also recently issued reports about the company. Zacks Research raised BioLife Solutions from a “hold” rating to a “strong-buy” rating in a research note on Friday, January 23rd. UBS Group reaffirmed a “buy” rating on shares of BioLife Solutions in a research report on Monday, December 29th. HC Wainwright reissued a “buy” rating and issued a $32.00 target price on shares of BioLife Solutions in a research report on Monday, December 29th. Weiss Ratings restated a “sell (d-)” rating on shares of BioLife Solutions in a research note on Wednesday, January 21st. Finally, Northland Securities set a $34.00 price target on shares of BioLife Solutions in a report on Monday, January 5th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $32.00.

BioLife Solutions Trading Up 7.7%

NASDAQ BLFS opened at $24.20 on Friday. BioLife Solutions has a 1-year low of $19.10 and a 1-year high of $29.62. The firm’s fifty day simple moving average is $23.83 and its 200-day simple moving average is $25.21. The company has a market capitalization of $1.17 billion, a PE ratio of -219.98 and a beta of 1.92.

Insider Transactions at BioLife Solutions

In other BioLife Solutions news, Director Amy Duross sold 2,000 shares of the company’s stock in a transaction dated Monday, December 15th. The shares were sold at an average price of $24.60, for a total transaction of $49,200.00. Following the completion of the sale, the director directly owned 18,687 shares in the company, valued at $459,700.20. This represents a 9.67% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Troy Wichterman sold 990 shares of the business’s stock in a transaction dated Tuesday, January 6th. The stock was sold at an average price of $25.59, for a total value of $25,334.10. Following the transaction, the chief financial officer directly owned 150,746 shares of the company’s stock, valued at $3,857,590.14. This represents a 0.65% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 37,802 shares of company stock valued at $967,191 over the last 90 days. Corporate insiders own 2.20% of the company’s stock.

Hedge Funds Weigh In On BioLife Solutions

Several institutional investors and hedge funds have recently added to or reduced their stakes in BLFS. T. Rowe Price Investment Management Inc. lifted its position in shares of BioLife Solutions by 27.4% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 5,180,824 shares of the medical equipment provider’s stock worth $125,273,000 after acquiring an additional 1,113,972 shares during the period. Invesco Ltd. raised its stake in shares of BioLife Solutions by 9.2% in the fourth quarter. Invesco Ltd. now owns 3,932,191 shares of the medical equipment provider’s stock valued at $95,080,000 after purchasing an additional 332,747 shares in the last quarter. XTX Topco Ltd lifted its position in BioLife Solutions by 280.4% in the fourth quarter. XTX Topco Ltd now owns 36,262 shares of the medical equipment provider’s stock worth $877,000 after purchasing an additional 26,729 shares during the period. SummitTX Capital L.P. bought a new position in BioLife Solutions in the fourth quarter worth $1,747,000. Finally, Sandler Capital Management acquired a new stake in BioLife Solutions during the fourth quarter worth $765,000. 93.24% of the stock is currently owned by institutional investors.

More BioLife Solutions News

Here are the key news stories impacting BioLife Solutions this week:

• Positive Sentiment: Q4 results beat expectations — GAAP net income of $2.1M ($0.04/sh), revenue $24.8M (+20% YoY) and adjusted EBITDA of $6.9M (28% of revenue); management emphasized strong gross margins. BioLife Solutions Reports Fourth Quarter and Full Year 2025 Financial Results from Continuing Operations
• Positive Sentiment: Company set 2026 revenue guidance of $112.5M–$115.0M (implied 17–20% growth vs. 2025), above consensus — a clear near-term growth driver. BioLife Solutions outlines 17–20% revenue growth target for 2026 while expanding commercial customer mix
• Positive Sentiment: Quarterly EPS and revenue topped analyst estimates (EPS beat cited by Zacks and MarketBeat), reducing near-term earnings risk and supporting multiple expansion. BioLife Solutions Surpasses Q4 Earnings and Revenue Estimates (Zacks)
• Neutral Sentiment: Management discussed expansion of the commercial customer mix on the earnings call, which could raise upside if sustained but requires execution over 2026. BioLife Solutions Inc (BLFS) Q4 2025 Earnings Call Highlights
• Neutral Sentiment: Earnings call transcripts and full disclosures are available (InsiderMonkey / Seeking Alpha / Yahoo), useful for model updates but not new catalysts by themselves. Q4 2025 Earnings Call Transcript (InsiderMonkey)
• Negative Sentiment: Some third‑party summaries note a negative net‑margin metric and other minor discrepancies across outlets, which could create short-term confusion among investors until reconciled in filings. MarketBeat Q4 2025 Earnings Summary
• Negative Sentiment: Company did not provide clear EPS guidance in its FY2026 update (revenue guide provided but EPS line appeared blank in one release), which leaves earnings-per-share trajectory less certain. (Company disclosure)
• Neutral Sentiment: Reported short-interest data in public feeds showed anomalous zeros/NaN for February; no clear signal of a significant short-squeeze or bearish pressure at this time.

About BioLife Solutions

BioLife Solutions (NASDAQ:BLFS) specializes in biopreservation and cold chain workflow solutions for cell and gene therapies, regenerative medicine and other advanced biologics. The company develops and markets proprietary cryopreservation media and technology platforms designed to maintain cell viability and functionality during processing, storage and transport. BioLife’s product portfolio addresses critical steps in the manufacturing and distribution of cell-based products, helping life science researchers and biopharmaceutical manufacturers protect and preserve living cells.

The company’s flagship offerings include CryoStor, a family of serum-free cryopreservation media; HypoThermosol, a hypothermic storage solution for short-term cell and tissue preservation; and the ThawSTAR system, an automated cell thawing instrument that delivers controlled and reproducible warming of frozen cell therapies.